252 related articles for article (PubMed ID: 15634033)
1. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
[TBL] [Abstract][Full Text] [Related]
2. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
3. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884.
Fletcher CV; Acosta EP; Cheng H; Haubrich R; Fischl M; Raasch R; Mills C; Hu XJ; Katzenstein D; Remmel RP; Gulick RM;
AIDS; 2000 Nov; 14(16):2495-501. PubMed ID: 11101060
[TBL] [Abstract][Full Text] [Related]
4. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams.
Morse GD; Reichman RC; Fischl MA; Para M; Leedom J; Powderly W; Demeter LM; Resnick L; Bassiakos Y; Timpone J; Cox S; Batts D
Antiviral Res; 2000 Jan; 45(1):47-58. PubMed ID: 10774589
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients.
Borin MT; Chambers JH; Carel BJ; Freimuth WW; Aksentijevich S; Piergies AA
Antiviral Res; 1997 Jun; 35(1):53-63. PubMed ID: 9224961
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Kappelhoff BS; Huitema AD; Yalvaç Z; Prins JM; Mulder JW; Meenhorst PL; Beijnen JH
Clin Pharmacokinet; 2005; 44(8):849-61. PubMed ID: 16029069
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.
Csajka C; Marzolini C; Fattinger K; Décosterd LA; Fellay J; Telenti A; Biollaz J; Buclin T
Clin Pharmacol Ther; 2003 Jan; 73(1):20-30. PubMed ID: 12545140
[TBL] [Abstract][Full Text] [Related]
8. Delavirdine: clinical pharmacokinetics and drug interactions.
Tran JQ; Gerber JG; Kerr BM
Clin Pharmacokinet; 2001; 40(3):207-26. PubMed ID: 11327199
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients.
Shelton MJ; Hewitt RG; Adams J; Della-Coletta A; Cox S; Morse GD
Antimicrob Agents Chemother; 2003 May; 47(5):1694-9. PubMed ID: 12709342
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M; Lubomirov R; Fayet-Mello A; Aouri M; Rotger M; Buclin T; Widmer N; Gatri M; Ledergerber B; Rentsch K; Cavassini M; Panchaud A; Guidi M; Telenti A; Décosterd LA; Csajka C;
J Antimicrob Chemother; 2014 Sep; 69(9):2489-98. PubMed ID: 24821595
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate.
Borin MT; Chambers JH; Carel BJ; Gagnon S; Freimuth WW
Clin Pharmacol Ther; 1997 May; 61(5):544-53. PubMed ID: 9164416
[TBL] [Abstract][Full Text] [Related]
15. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients.
Sam WJ; Tham LS; Holmes MJ; Aw M; Quak SH; Lee KH; Lim SG; Prabhakaran K; Chan SY; Ho PC
Clin Pharmacokinet; 2006; 45(1):59-75. PubMed ID: 16430311
[TBL] [Abstract][Full Text] [Related]
17. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW
Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Panhard X; Legrand M; Taburet AM; Diquet B; Goujard C; Mentré F;
Eur J Clin Pharmacol; 2007 Nov; 63(11):1019-29. PubMed ID: 17694300
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir.
Tran JQ; Petersen C; Garrett M; Hee B; Kerr BM
Clin Pharmacol Ther; 2002 Dec; 72(6):615-26. PubMed ID: 12496743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
